A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Trial Profile

A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Gallium 68 PSMA R2 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Acronyms PROfind
  • Sponsors Advanced Accelerator Applications
  • Most Recent Events

    • 22 Jun 2018 According to the Advanced Accelerator Applications media release, first patient has been dosed in this study.
    • 05 Jun 2018 Planned End Date changed from 3 Jun 2019 to 23 Jun 2019.
    • 05 Jun 2018 Planned primary completion date changed from 3 Jun 2019 to 23 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top